Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

9.84EUR
2 Dec 2016
Change (% chg)

€-0.06 (-0.65%)
Prev Close
€9.90
Open
€9.90
Day's High
€9.90
Day's Low
€9.81
Volume
80,181
Avg. Vol
213,346
52-wk High
€16.20
52-wk Low
€8.21

Latest Key Developments (Source: Significant Developments)

Ablynx H1 net income turns to profit of 22.8 million euros
Thursday, 25 Aug 2016 01:00am EDT 

Ablynx NV : H1 total revenues were 53.5 million euros ($60.3 million), a 39 pct increase compared with 2015 . H1 operating loss reduced to 2.0 million euros, compared with 7.4 million euros in 2015 . H1 net profit of 22.8 million euros versus loss of 15.2 million euros year ago .Outlook for remainder of year confirmed.  Full Article

Bank of America Corporation announce 5.24 pct shareholding in Ablynx
Thursday, 4 Aug 2016 01:00am EDT 

Ablynx NV :Bank of America Corporation announce 5.24 pct shareholding in Ablynx.  Full Article

Ablynx CEO sees potential multibillion-dollar opportunity for drug
Thursday, 7 Jul 2016 04:22am EDT 

Ablynx CEO Edwin Moses told Reuters: Sales opportunity for vobarilizumab could be in "billions" of dollars in rheumatoid arthritis & other diseases . AbbVie will decide later in 2016 whether to license vobarilizumab, after second RA trial results expected in August Further company coverage: [ABLX.BR] (Reporting by UK bureau) ((uk.online@reuters.com;)).  Full Article

Vectura says Ablynx to exercise a license option on Fox device
Tuesday, 28 Jun 2016 04:57am EDT 

Vectura Group Plc :Ablynx to exercise option to license Vectura's Fox device for use in its forthcoming phase IIB efficacy study of its inhaled anti-rsv nanobody.  Full Article

Van Herk Investments announce 3.02 pct shareholding in Ablynx
Thursday, 16 Jun 2016 01:00am EDT 

Ablynx NV :Van Herk Investments announce 3.02 pct shareholding in Ablynx.  Full Article

Ablynx successfully raises 74.2 mln euros
Thursday, 2 Jun 2016 03:17am EDT 

Ablynx NV : Announced on Wednesday that it has raised 74.2 million euros ($83.1 million) through a private placement of new shares via an accelerated book building procedure announced on June 1, 2016 .Has placed 5,533,720 new shares with domestic and international institutional investors at a price of 13.40 euros per share, i.e. a 6.29 pct discount to June 1 closing price.  Full Article

Ablynx to raise capital through private placement of new shares
Wednesday, 1 Jun 2016 11:42am EDT 

Ablynx Nv : To raise capital through a private placement of new shares . To raise gross proceeds of up to approximately 60 million euro ($67.0 million) .J.P. MORGAN Securities Plc, Jefferies International Limited and KBC Securities are acting as joint bookrunners.  Full Article

Ablynx Q1 cash position up at 233.7 million euros
Thursday, 12 May 2016 01:01am EDT 

Ablynx NV : Q1 revenues up 94 pct to 27.4 million euros ($31.3 million)(Q1 2015: 14.1 million euros) . Q1 233.7 million euros in cash, cash equivalents, restricted cash and short-term investments (Q1 2015: 193.3 million euros) . Q1 operating result of negative 0.7 million euros (Q1 2015: loss of 5.0 million euros) . Financial guidance and 2016 outlook confirmed . Company reiterates its net cash burn guidance for the full year 2016 of 65-75 million euros . In Q4 Ablynx expects to start a phase II efficacy study with the wholly-owned inhaled anti-rsv nanobody, ALX-0171 .In Q3, expects that the first patients from the phase III HERCULES study of its wholly-owned anti-vwf nanobody, caplacizumab, will have rolled-over into a 3 year follow-up study.  Full Article

Ablynx meets primary endpoint in anti-RSV nanobody phase I/IIa study
Tuesday, 3 May 2016 01:00am EDT 

Ablynx NV:Reports positive top line results for its inhaled anti-RSV nanobody (ALX-0171) in a phase I/IIa study in infants hospitalized with an RSV infection.Primary endpoint of safety and tolerability met.Anti-viral effect demonstrated and encouraging initial indication of therapeutic effect.Results support advancing programme into a phase II efficacy study in infants.Potential general proof-of-principle for administration of nanobodies by inhalation.  Full Article

Ablynx to receive EUR 8 mln milestone as Boehringer Ingelheim starts Phase I study
Thursday, 21 Apr 2016 01:00am EDT 

Ablynx NV:Ablynx to receive an 8 million euros milestone as Boehringer Ingelheim starts a Phase I study with an anti-CX3CR1 nanobody.  Full Article

BRIEF-Ablynx 9-month net profit turns to 10.9 million euros

* 9-month revenue 68.9 million euros ($73.22 million) versus 53.6 million euros year ago